Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-02 am EST
49.35 CHF   -0.80%
11/24Basilea Pharmaceutica : Updated November 24, 2022
PU
11/02Basilea To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-Seven Therapeutics
MT
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea Pharmaceutica AG Enters into Asset Purchase Agreement and Sub-License Agreement with SillaJen, Inc

09/20/2022 | 01:15am EST

Basilea Pharmaceutica Ltd. announced that it has entered into an asset purchase agreement and a sub-license agreement with SillaJen Inc. for Basilea's novel kinase inhibitor, BAL0891, a potential first-in-class mitotic checkpoint inhibitor, that drives aberrant tumor cell division leading to tumor cell death. Basilea in-licensed BAL0891 in 2018 from the Dutch precision medicine company NTRC. Under the asset purchase agreement Basilea is selling its intellectual property rights generated under the license and collaboration agreement with NTRC.

In addition, Basilea is sub-licensing its rights and obligations under the license and collaboration agreement with NTRC to SillaJen. Under the terms of the agreement, Basilea will receive upfront and near-term milestone payments of USD 14 million. Basilea is also eligible to receive further payments of up to approximately USD 320 million upon the achievement of predefined development, regulatory and sales milestones and tiered royalties on net sales starting in the single digit range going up to double-digits.

Basilea remains responsible for making milestone and royalty payments to NTRC according to the license and collaboration agreement with NTRC. In February this year Basilea announced its intention to focus on becoming a leading anti-infectives company and therefore to separate its oncology assets. Basilea has already made significant progress in the implementation of the new strategy and expects no material expenses related to oncology activities beyond 2022.

Basilea is on track to achieve sustainable profitability from 2023.


ę S&P Capital IQ 2022
All news about BASILEA PHARMACEUTICA AG
11/24Basilea Pharmaceutica : Updated November 24, 2022
PU
11/02Basilea To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-Seven Therapeutics
MT
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutic..
GL
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutic..
DJ
10/26Basilea Pharmaceutica : Updated October 26, 2022
PU
10/24Basilea to Submit New Drug Application for Bloodstream Infection Drug Ceftobiprole in 2..
MT
10/24ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the tre..
GL
10/24ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the tre..
AQ
10/24Basilea : ERADICATE phase 3 study results highlight the potential role of ceftob..
DJ
10/24Basilea Pharmaceutica AG 's ERADICATE Phase 3 Study Results Highlight the Potential Rol..
CI
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2022 115 M 123 M 123 M
Net income 2022 -21,3 M -22,6 M -22,6 M
Net Debt 2022 98,1 M 104 M 104 M
P/E ratio 2022 -26,9x
Yield 2022 -
Capitalization 588 M 626 M 626 M
EV / Sales 2022 5,96x
EV / Sales 2023 4,79x
Nbr of Employees 177
Free-Float 88,1%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 49,35 CHF
Average target price 68,58 CHF
Spread / Average Target 39,0%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG20.60%626
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727